Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × Homoharringtonine × Clear all

NCT02159872 2021-06-09

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Phase 2 Completed

48 enrolled 9 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes